However, patients with BRAFV600E mutant cutaneous metastatic melanoma enrolled in clinical trials testing MEK inhibitors [25,26] have lower response rates than the use of the type I BRAF inhibitors vemurafenib or dabrafenib (GSK2118436) in the same population [11,13,27]. The gene discussed is MAP2K7; the disease is metastatic melanoma.